Professional Documents
Culture Documents
SECTION 1A
Ajay Munjal
Rajendra Singh
Garima Kalra
Megha Ahlowalia
1
Ashu Negi
CONTENTS
Definition
Classification 1 2 3
Regulatory environment
Patent laws
Key players
SWOT analysis
“Indian pharmaceutical industry can be defined as a
success story providing employment to millions
and ensuring that essential drugs are available at
affordable prices to the vast population of Indian
sub-continent”
-RICHARD GESTER
(Economist)
CLASSIFICATION-1
ORGANIZED UNORGANIZED
4
CLASSIFICATION-2
5
CLASSIFICATION-3
PATENT
BRANDED
ethical formulations
prepared using a bulk drug GENERICS
under product patent Formulations that do not contain any patented
are marketed by a single Bulk drugs and can be manufactured by more
pharmaceutical company. Than 1 company.
6
FACTS & FIGURES
Globally, India is
Witnessing a growth rate of about 10% over the last few years.
7
EXISTING
8
PATENT LAWS
9
PATENT LAW
10
EFFECTS OF PATENT ACT 2005
11
Key Players
12
STRENGTH
Cost effective technology
Strong and well-developed manufacturing base
Clinical research and trials
Knowledge based, low- cost manpower in science & technology
Proficiency in path-breaking research
High-quality formulations and drugs
High standards of purity
Non-infringing processes of Active Pharmaceutical Ingredients (APIs)
Future growth driver
World-class process development labs
Excellent clinical trial centers
Chemical and process development competencies
13
WEAKNESS
Fragmented capacities
14
OPPORTUNITIES
Incredible export potential
Increasing health consciousness
New innovative therapeutic products
Globalization
Drug delivery system management
Increased incomes
Production of generic drugs
Contract manufacturing
Clinical trials & research
Drug molecules
15
THREATS
16